Order Description

Title of Paper: warfarin versus NOACs in treating atrial fibrillation
Section I — General information on atrial fibrillation in regards to anticoagulant
A. what is atrial fibrillation
2014 AHA/ACC/HRS guidelines

B. what are common signs and symptoms associated with AF?
C. laboratories findings
D. when is it indicated to use an anticoagulant in treating atrial fibrillation?
AHA/ACC 2014 guidelines
CHEST 2012 guidelines

E. what anticoagulant is preferred to treat atrial fibrillation?

Section II – warfarin and NOACs drugs

FEEL FREE TO ADD ANY OTHER GENERAL INFORMATION REGARDING DRUGS A-E THAT MAY BE RELEVANT

A. warfarin
• what is warfarin
• What is the mechanism of action of warfarin?
• PK parameters
• What are the dosing and monitoring parameters?
• What are the drugs and foods interactions associated with warfarin?
• Vitamin K: antidote of warfarin
• contraindications

B. dabigatran
• what is dabigatran?
• What are the dosing and monitoring parameters?
• What is the mechanism of action?
• Drugs interactions associated with dabigatran
• Contraindications
• PK parameters
• Idarucizumab: antidote of dabigatran
Dosing and monitoring parameters

Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. New England Journal of Medicine. 2015;373(6):511-520. doi:10.1056/nejmoa1502000.

C. rivaroxaban
• what is rivaroxaban?
• What is the mechanism of action?
• Dosing and monitoring parameters
• Drugs interactions
• Contraindications
• PK parameters

D. apixaban
• what is apixaban?
• What is the mechanism of action?
• What is the investigational agent?
• Dosing and monitoring parameters
• Drugs interactions
• Contraindications
• PK parameters

E. edoxaban
• what is edoxaban?
• What is the mechanism of action?
• Dosing and monitoring parameters
• PK parameters
• Drugs interactions
• contraindications

Section III – Comparison of the efficacy and safety of NOACs with warfarin in patient with AF
THIS IS THE BULK OF THE PAPER!
In this section, comparison will be made in terms of efficacy, safety, stroke prevention, rapid onset and offset of action, and lower incidence of bleeding. Overall, you will need to discuss phase III trials for each of these. Please use the New England Journal of Medicine for each of them as the one I cited below and other literature can be used as supplement reference
A. Comparison of warfarin to dabigatran
B. Comparison of warfarin to rivaroxaban
C. Comparison of warfarin to apixaban
D. Comparison of warfarin to edoxaban

Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 2009;361(12):1139-1151. doi:10.1056/nejmoa0905561.
Rasmussen, Lars Hvilsted et al. “Primary and Secondary Prevention with New Oral Anticoagulant Drugs for Stroke Prevention in Atrial Fibrillation: Indirect Comparison Analysis.” The BMJ 345 (2012): e7097. PMC. Web. 17 Feb. 2017.

Section IV – conclusion

A. Wrap up of the entire paper
B. What is the more efficient anticoagulant therapy for the treatment of AF?
For this section, I need at least 2 articles comparing these anticoagulants to answer this question
C. Meta-analysis comparing efficacy and safety of NOACs in treating atrial fibrillation
For this section, you will have to compare individually one of the NOAC’s drug to other

Rasmussen, Lars Hvilsted et al. “Primary and Secondary Prevention with New Oral Anticoagulant Drugs for Stroke Prevention in Atrial Fibrillation: Indirect Comparison Analysis.” The BMJ 345 (2012): e7097. PMC. Web. 17 Feb. 2017.

the font of the paper has to be 10

At least 7 sources have to be peer review journal articles or scholarly books. the majority of sources used have to be primary literature or tertiary literature.

The proposed outline could be adjusted if needed for a better flow and coherence in the paper. Please focus more on section III and it has to be at least 4 pages long. Proposed sources may not necessarily be used, but i really want to use the guidelines mentioned in the outline and the new england journal of medicine.